Search results
Results From The WOW.Com Content Network
EE/CPA is used as a combined birth control pill to prevent ovulation and pregnancy in women. [2] It is also approved and used to treat androgen-dependent conditions in women such as acne , seborrhea , hirsutism , female pattern hair loss , and hyperandrogenism due to polycystic ovary syndrome .
If used exactly as instructed, the estimated risk of getting pregnant is 0.3% which means that about 3 in 1000 women on combined oral contraceptive pills will become pregnant within one year. [40] However, typical use of combined oral contraceptive pills by users often consists of timing errors, forgotten pills, or unwanted side effects.
Progestogen-only pills (POPs), colloquially known as "mini pills", are a type of oral contraceptive that contain synthetic progestogens and do not contain estrogens. [4] They are primarily used for the prevention of undesired pregnancy, although additional medical uses also exist.
Oral contraceptives, abbreviated OCPs, also known as birth control pills, are medications taken by mouth for the purpose of birth control. The introduction of the birth control pill ("the Pill") in 1960 revolutionized the options for contraception, sparking vibrant discussion in the scientific and social science literature and in the media.
A method that suited you when you were 18 might not when you are 28, 38 or 48, says Paula Baraitser, medical director of the NHS-partnered free sexual health service provider SH:24.
Signs and symptoms of pregnancy are common, benign conditions that result from the changes to the body that occur during pregnancy. Signs and symptoms of pregnancy typically change as pregnancy progresses, although several symptoms may be present throughout. Depending on severity, common symptoms in pregnancy can develop into complications. [1 ...
This can make it difficult to catch early. Other signs of valve damage include dizziness, a painful red rash on the lower extremities and bluish discoloration of the fingernails and toenails. If ...
A 2012 meta-analysis estimated that the absolute risk of VTE is 2 per 10,000 women for non-use, 8 per 10,000 women for ethinylestradiol and levonorgestrel-containing birth control pills, and 10 to 15 per 10,000 women for birth control pills containing ethinylestradiol and a newer-generation progestin. [76]